BioCardia to Participate in Upcoming Investor Conferences
08/13/2021 - 08:00 AM
SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia® , Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company’s management team will participate in the following upcoming investor conferences:
Q3 Investor Summit Virtual Conference from August 17-18, 2021 https://investorsummitgroup.com/conferences/ BioCardia Corporate Presentation scheduled for 08/17 at 2pm Eastern Time (11am Pacific time) 1-1 meetings available with Company Representatives for those interested – please sign up through conference website. SNN Network Virtual Event Conference from August 17-19, 2021 https://conference.snn.network/ BioCardia Corporate Presentation scheduled for 08/19 at 3pm Eastern Time (12pm Pacific time) 1-1 meetings available with Company Representatives for those interested – please sign up through conference website. About BioCardia®
BioCardia, Inc. , headquartered in San Carlos, California, is a developer of two biotherapeutic platforms – the CardiAMPTM autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. These platforms underly four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Company’s proprietary biotherapeutic delivery platforms, which the Company also selectively licenses to other biotherapeutic development firms.INVESTOR CONTACT: David McClung, Chief Financial Officerinvestors@BioCardia.com (650) 226-0120
MEDIA CONTACT: Anne Laluc, Marketing Email: alaluc@biocardia.com Phone: 650-226-0120
BCDA Rankings
N/A Ranked by Stock Gains
BCDA Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Biotechnology, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
San Carlos
About BCDA
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.